Avrobio Stock (AVRO): Why The Price Substantially Fell

By Amit Chowdhry ● Jan 5, 2022
  • The stock price of Avrobio Inc (NASDAQ: AVRO) fell by 36.63% in the most recent trading session. This is why it happened.

The stock price of Avrobio Inc (NASDAQ: AVRO) – a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease – fell by 36.63% in the most recent trading session. Investors are responding negatively to AVROBIO announcing that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024.

The company is deprioritizing its Fabry disease program due to several factors, including new clinical data showing variable engraftment patterns from the five most recently dosed Phase 2 FAB-GT patients which would significantly extend the program’s development timeline, as well as an increasingly challenging market and regulatory environment for Fabry disease.


“Following steady progress in 2021, we have reset our corporate priorities and will extend our cash runway to strengthen our ability to deliver on the promise of our gene therapy programs. Powered by our proprietary plato gene therapy platform, we will focus our efforts on moving value driving clinical-stage programs forward in 2022, with data updates expected for our cystinosis and Gaucher disease type 1 programs, as well as regulatory interactions anticipated across multiple programs in our pipeline.”

“Previously reported data from 13 patients treated across our three clinical-stage programs have shown durable engraftment out 9 to 54 months. It is the new data from the five most recently dosed Phase 2 FAB-GT patients that are discordant with these other data and show variable engraftment. In addition, the last 12 months have presented multiple challenging market and regulatory dynamics for our Fabry disease program, which would now be exacerbated by a meaningfully extended development timeline. We’re fully aware of the impact this difficult decision has on the patients and families whom we have had the privilege to get to know over the years, but we believe deprioritizing and halting enrollment in our Fabry disease program is the right step forward for AVROBIO and preserves our ability to continue developing therapies with the potential to address urgent unmet needs in the lysosomal disorder community.”

— Geoff MacKay, president and CEO of AVROBIO

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.